Published : 07 Apr 2023

---

Aagami has a new client. This time it is an Award-winning New York biotech specializing in molecular engineering, RNAi and CRISPR/Cas9 technologies. 

 

For partnering with Cell and Gene therapy companies, our client brings advanced RNAi technologies and tools:

 

Best in class RNAi tools

·      Proprietary amiRNA scaffolds with enhanced silencing potential

·      Vector designs for efficient delivery and expression

·      Multi-miR for multiple gene silencing using concatemers of amiRNAs

AAV RNAi-based gene therapy

·      Tissue-specific delivery

·      Long-term efficacy in vivo

Next-gen RNAi therapeutics

·      Design features to limit off-target effects

·      Coupling to unique ligand-based delivery modalities

·      In vivo reporter model to assess bioavailability, efficacy and toxicities

The assignment received by Aagami is to support their market expansion needs. A team of 3 professionals at Aagami will work with focus to bring business to the client.